Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
Authors' conclusion
With twice daily, on-demand calibration, the inpatient CGM use was safe for insulin dosing, decreasing the frequency of glucometer fingersticks. For glucose levels >70 mg/dL, CGMs showed adequate accuracy, without interference from vital and laboratory values.
Study context
- Population
- Adults hospitalized with COVID-19 and hyperglycemia812 paired values
- Participants
- 20 adults
- Exposure
- CGM vs glucometer readings
- Outcome
- CGM accuracy against glucometer, expressed as mean absolute relative difference (MARD)
Methodological detailssingle-centre, tertiary care center, remotely monitored CGM
- Single-centre
- Tertiary care center
- Remotely monitored CGM
Main finding
As reported in the abstract
Aggregate MARD of CGM vs glucometer
Aggregate mean absolute relative difference (MARD)
10.4%
MARD for time in range
11.4%
MARD for grade 1 hyperglycemia
9.4%
MARD for grade 2 hyperglycemia
9.1%
Observational data: associations, not effects.
Further findings
MARD correlation with vital and laboratory values
- No MARD correlation with mean arterial blood pressure, oxygen saturation, daily hemoglobin or glomerular filtration rates
Frequency of glucometer measurements · after CGM placement
- Glucometer measurements per day decreased from 5 to 3 and then 2
Safety
CGM clinical reliability (Clarke error grid)
- CGM values within the "safe" zones of Clarke error grid
- 99.7%
Original publication
Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center. Endocr Pract. Published 22 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →